OIG Issues Favorable Advisory Opinion Involving Financial Risk Mitigation Arrangements for High-Cost Rare Disease Drug

On June 20, 2024, the U.S. Department of Health and Human Services Office of Inspector General (“OIG”) posted Advisory Opinion 24-04, a favorable opinion analyzing a refund and discount program designed to alleviate the financial risks associated with the purchase of a high-cost drug in the rare disease space. The advisory opinion was issued at……
By: Arnall Golden Gregory LLP